VIP126
1 abstract
Abstract
An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, and pharmacokinetics of VIP236 monotherapy in patients with advanced cancer.Org: Adelaide Cancer Center, ICON Cancer Care, Austin, TX, Adelaide Cancer Center, Brisbane, Australia,